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The antiviral and immunomodula tory effects of interferon were
assessed in the treatment of chronic Hepatitis C in multi-ethnic
patients to prevent viral replication and chronic liver damage. Three
million units of recombinant interferon alpha-2b were administered
three times a week for 48 weeks to a group of 9 active Hepatitis C
patients. A clinical response was defined as normalization of serum
ALT values. Serum was frozen and stored for Hepatitis C viral
assays. Four patients normalized their liver functions. When viral
levels were measured only two patients had unmeasurable levels of
HCV RNA after treatment. Therapeutic results were observed and
much work needs to be done to improve therapy because a serious
epidemic is predicted for the future.
Introduction
The Federal Drug Adminstration approved Interferon alpha-2b
for the treatment of chronic Hepatitis C in February 1991. The
Hepatitis C antigen was identified in 1989 and an antibody test
developed soon thereafter; prior to this, Hepatitis C was referred to
as Non-A Non-B Hepatitis. Interferon has been shown currently to
be the most effective therapy in approximately 30 to 40% of chronic
Hepatitis C patients1-3because of its antiviral and immunomodulatory
effects. The reports leading to FDA approval looked promising so
interferon therapy was utilized for our patients soon after FDA
approval and forms the basis for this report of our early experiences.
Our group was referred the Hepatitis C Virus (HCV) cases for
treatment because of our experience in a research project to treat
chronic Hepatitis B patients.4
Chronic Hepatitis B is a major public health problem in Hawaii
because of the large immigrant population from Asia and the Pacific
Basin. Exposure to Hepatitis B virus (HBV) often results in chronic
Hepatitis that can significantly increase the risk of developing
cirrhosis and hepatocellular carcinoma. Hepatitis C can develop into
these same fatal complications. The recent NIH Consensus Confer
ence on Hepatitis C notes that 4 million people in the United States
are currently infected with HCV with about 30,000 new cases a year
with the numbers to double or triple in the next 20 to 30 years.5It will
be a major public health problem until an effective therapy and
vaccine can be developed.
Materials and Methods
Patient Population
Patients testing positive for the first generation HCV antibody test
(Ortho Diagnostics, New Jersey) and negative for Hepatitis B
antigens or antibodies were referred for evaluation for treatment.
Patients with elevated liver function tests, primarily ALT >=1 .5X
high normal level for over 6 months, were then selected for treatment
according to the FDA approved protocol. Patients were excluded if
they showed evidence of cirrhosis as reflected in their alkaline
phosphatase levels. Informed consent was obtained.
Interferon Therapy
Chronic active Hepatitis C patients were treated with recombinant
interferon alpha-2b (Intron-A, Schering-Plough Corporation,
Kenilworth, NJ). Three million units were administered subcutane
ously 3 times per week for 48 weeks. If there was no clinical reponse,
another 48 week course was offered . Patients received their injec
tions in the Ambulatory Oncology Clinic or chose to voluntarily
self-administer their medication after training by the Oncology
Nursing Staff. The dose was reduced to 1-2 million units when
platelets were <100,000 or granulocytes were <1000.
Evaluation During Therapy
Patients were evaluated during therapy for hematological and
biochemical profiles. Blood was collected for complete blood and
platelet counts and liver function tests (LFrs) including serum
alanine and aspartate aminotransferase and gamma glutamyl
transpeptidase activities (ALT, AST, GGPT) prior to therapy, after
2 weeks, monthly during therapy and 2-3 months post therapy. Liver
function tests were performed by Immunoassay (EIA) (Abbott
Laboratories, Abbott Park, IL). All evaluations were performed by
the same Clinical Laboratory. A clincal response was defined as
normalization of ALT levels.
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Hepatitis C Virus (HCV) Assay
Aliquots of serial serum samples from each patient were drawn at
baseline, 2-3 month intervals during therapy, the end of therapy and
2-3 months following therapy and stored at -70 C for analysis when
more specific viral tests were available. The first generation test for
HCV antibody was performed in the clinical laboratory. Sera drawn
during therapy were frozen for later batch analysis for HCV-RNA
by reverse transcription-polymerase reaction (RT-PCR) by Lawrence
Lumeng MD, Department of Gastroenterology, Indiana University
School of Medicine. RT-PCR analysis for the 256BP and 157BP
regions confirmed the diagnosis of HCV but it was only semi-
quantitative.
Branched HCV RNA analysis was performed by Reference
Laboratory Alliance (Pittsburgh, PA).6HCV-RNA is quantifiable at
levels >3.5X10E÷5 Eq/ml butis notFDAclearedfordiagnostic use
and may not constitute the sole basis for patient diagnosis. HCV
RNA in a patient’s sample is captured and hybridized to several
target probes corresponding to the conserved 5’ nontranslated
region of HCV. Amplification of signal from the hybridizations is
achieved by addition of branched DNA molecules which can bind
multiple copies of enzyme emitted and measured by a luminometer.
Concentrations of viral target in individual specimens were deter
mined by comparison with a standard curve.
HCV genotype determination was performed on the baseline
samples by RT-PCR at Reference Laboratory Alliance (Pittsburgh,
PA). The 1NNO-LIPA (line probe assay) is a reverse hybridization
for the differentiation of the various HCV genotypes. DNA repre
senting a sequence from the 5’ nontranslated region was amplified
using biotinylated primers. Amplified DNA was hybridized to
specific oligonucleotide-probes immobilized on membrane strips.
Hybridizations were visualized by reaction of alkaline phosphatase,
bound to amplified DNA, with chromogenic substrate. The pattern
of reactivity of a simplified fragment with one or more lines upon the
test strip allows recognition of five major HCV genotypes (Geno
type 1-5) and 6 subtypes (la, lb. 2a, 2b, 3a,3b).
Statistical Analysis
Results are expressed as arithmetic mean ± SD except where
noted. Data was analyzed with the Sigma Stat program (Jandel
Scientific, San Rafael, CA). Continuous variables were analyzed by
linear regression or Analysis of Variation (ANOVA) techniques.
The IBM 55SX -PS2 computer was used for the analysis.
Results
Study Population
Eleven patients were referred for evaluation for treatment; one
patient did not qualify because of associated Hepatitis B involve
ment and evidence of cirrhosis. One of the remaining ten patients
was a young patient from a drug rehabilitation program who ran
away from his program and did not return for further treatment after
his first injection. The remaining nine patients treated ranged in ages
of 35-69 years; 6 of the 9 were males. Baseline liver function tests
(ALT, AST and GGPT) were increased in the patients: ALT = 195
± 121 IU/L,AST= 111 ±64IUIL,GGPT= 115± IO9IUIL.Therisk
factors identified for Hepatitis C were blood or blood products
transfusion (3) and confessed unspecified drug usage (2); no history
of any other recognized risk factor was obtained from the remaining
4 patients. There was only one foreign born patient (Korea); the
remaining patients were from Hawaii, Guam or the mainland US.
Toxicity
Patients initially experienced flu-like symptoms, including myal
gia, headache and fever which generally improved after the first
week or two of therapy; one patient (#905) had severe constitutional
symptoms which responded to dose reduction. The nine patients
tolerated their regimens and completed therapy. One patient (#934)
required dose reductions due to decrease in wbc’s and platelets.
Biochemical Liver Function Tests
ALT levels decreased in all patients during treatment, P<.05
(Fig 1), but only 4 patients normalized their ALT levels. One patient,
#905, who was infected after blood transfusion had normalized her
liver function tests after the first 6 months of treatment; she flared to
exceptionally high levels of ALT and was started on another course
of treatment. She responded to another 6 months of therapy with
continued normal liver function tests thereafter. The patients who
did not normalize had continued elevated levels or increased after
cessation of therapy.
Hepatitis C Virus (HCV) Assay
All patients were confirmed for the presence of HCV by PCR
analysis. Serial analysis during treatment of the patients only dem
onstrated the disappearance of both BP256 and BP157 markers in
one patient, again #905, demonstrating eradication ofthe virus. This
patient had flared her LFTs and required a second course of treat
ment.
Baseline levels of branched HCV RNA analysis ranged from 8.4-
862.7 IOE+5 Eq/mi. The 4 patients who normalized their LFTs had
baseline levels of 8.4, 26.6, 66.9 and 108.2 1OE+5 Eq/ml. Only two
of the four patients developed unmeasurable levels of HCV RNA
after therapy whose baseline levels were 8.4 and 26.6 respectively.
The lower baseline levels of HCV RNA may possibly predict a
better response.
HCV genotype analysis demonstrated a preponderance of geno
type 1, 7/9 patients. There was only single incidences of type 2 and
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Fig 1.—Changes in ALT levels of chronic active Hepatitis C patients on
interferon therapy,X±SD. Elevated levels at baselinedecreased but
not to normal levels in all patients.
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type 3 genotype groups. Three of the four
patients with a clinical response were type 1
or 1 band the fourth was type 3a; the complete
responder was type lb. The relationship of
branched chain HCV RNA levels and geno
type classification and clinical response is
summarized in Table 1.
Discussion
We were able to achieve a clinical response
in four out ofnine patients completing therapy
in this early utilization of Interferon alpha-2b
therapy for Hepatitis C infection which is
consistent with the results of other trials.
However, the antiviral effect of interferon did
not correspond to the clinical response; only
two patients achieved unmeasurable levels of
HCV RNA and only one of these two had no
trace ofHCV with the sensitive PCR analysis.
Grecht et a16 report that high viremia titers
were associated with advanced stages of the
disease. Low baseline HCV RNA levels are
reported by other investigators7’8to be predic
tors of successful therapy, which may also be
seen in some of our responders to interferon
treatment.
In the United States, genotype I accounts
for about 75% of chronic HCV infections
with half belonging to the 1 a subtype and half
to the lb subtype. Genotype 2 accounts for
10-20% of isolates in the US and genotype 3
for another 5% of isolates. The distribution of
HCV genotype in our study group follows
these reports. Genotypes 4, 5 and 6 are rarely
seen in the USA and when identified usually
represents infection acquired abroad. Studies
have documented higher rates of long-term
response to alpha interferon in patients in
fected with genotypes 2a, 2b, or 3a compared
with genotype 1 .°“ Chemello and Alberti’2
reports only 29% long term response for type
1, versus 52% for type 2 and 74% for type 3
patients. The predominanace of type 1 virus
in Hawaii demonstrates a lowered chance of
successful therapy in our patients. In contrast
type 2 predominates in the Japanese patients
(69%) with 18 (%) Type 3; this gives them a
greater probability of successful therapy than
our population)3 One type 3 patient had a
clinical response and developed unmeasurable
levels of HCV RNA. The one complete re
sponder to all three viral measurements was
genotype ib; three of four clinical responders
were serotype lb or 1. In this study the geno
type of HCV did not aid in identifying prob
able reponders except for one type 3 patient
who had a low level of HCV RNA (8.4) at
baseline.
Interferon still remains the only effective treatment for Hepatitis
C infection at present. The optimal duration and dose may still need
to be determined. Early trials suggested a better response at higher
doses; it has been recommended that patients unresponsive to the
standard dose be treated with higher doses.14 Bellary et al’5 utilized
a dose of 5 million units three times a week for 6 months and
achieved a 59% reponse rate, but 50% of those with a total reponse
had a relapse. Lindsay et al’6 evaluated response rates of 3,5, or 10
million units given thrice weekly for 12 weeks; those not responding
after 12 weeks were then randomized to additional therapy at either
the same or higher dose for an additional 12 to 36 weeks. They
concluded that the initial response to interferon was not increased by
treatment with higher doses of the drug; although marginal, the
additional higher doses may still be worth the risk of intolerance to
the medication. Vogel et al’7 and Ferenci Pet al’8 in Austria reported
improved response to doses up to 10 million units but there was
varying intolerance to the medication. The treatment may also need
to be extended for longer periods as well as an increase in dosage.
The toxicity and expense of such regimens must be considered if this
is comtemplated. Poynard et al’9 extended the interferon treatment
randomly for another 12 months after their patients had been treated
for 6 months. Those receiving the same dose for an additional 12
months demonstrated a higher percentage with complete ALT and
liver histologic reponse.
This early trial reveals only a 4/9 clinical response to Interferon
alpha-2b and only 2/9 developed unmeasurable levels of the Hepa
titis C virus. Further trials are required since interferon is the only
effective treatment at this time.
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Table 1.—Viral Genotype, HCV-RNA and Clinical Response
Patient Sex Genotype Clinical HCV HCV
No. Response RNA RNA
Baseline End
904 F 1 + 108.2 104.3
905* F lb + 26.6 <3.4
910 M la - 862.7 109.4
913 M 1 - 113.1 140.4
934* M lb - 45.6 44.9
961 F 3a + 8.4 <3.4
962 M la - 186.9 19.4
963 M lb + 66.9 42.3
964 M 2b - 113.1 34
Reduction ** 1OE ÷ 5Eq/ml
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